Aldeyra Therapeutics Says Will Advance ADX-1612, An Investigational New HSP90 Inhibitor With 'Potential Nanomolar Potency' Against SARS-CoV-2, To Clinical Testing For COVID-19 Coronavirus; ADX-629 Accepted For BARDA CoronaWatch Meeting